Patent US4634971B1 successfully refreshed from Google Patents.
← Back to Patent Explorer
US4497805A Expired / Lapsed US ⏱️ 0.0 years remaining

11α-amino-androstanes

Assignee: BASELINE CAPITAL Corp
•
Filing: 1983-03-16
•
Granted: 1985-02-05
•
Expires: 2003-03-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compounds of the formula ##STR1## wherein R 1 is a C 1-8 alkyl group or a C 3-7 cycloalkyl group; R 2 is a C 1-6 alkyl group or a C 3-7 cycloalkyl group; R 3 is a hydroxy group or a group of formula --OR 4 or --OCOR 5 where R 4 is an alkyl or alkenyl group which may contain up to 6 carbon atoms (or such a group substituted by halogen, C 1-6 alkoxy, carboxyl, phenyl, phenyl substituted by nitro, halo, C 1-4 alkoxy or C 1-4 alkyl), a C 3-7 cycloalkyl group, a phenyl group (or such a group substituted by nitro, halo, C 1-4 alkoxy or C 1-4 alkyl), or a carbon-attached 5-7 membered heterocyclic ring in which the hetero atom is selected from nitrogen, oxygen and sulphur, and R 5 is a hydrogen atom or a group R 4 as defined above; and the D-homo analogues thereof having the group --CO 2 R 2 (wherein R 2 is as defined above) at the 17aβ-position, and salts thereof have activity as antidysrhythmic agents and may be applicable for the treatment of dysrhthmias in humans or animals. The compounds may be provided in the form of compositions in admixture with pharmaceutical carriers or excipients and may be prepared by a variety of processes known for producing steroids of this type. The invention also provides intermediates for the preparation of compounds of formula (I), in which intermediates R 1 and/or R 2 is replaced by a hydrogen atom, and processes for the preparation of such intermediates.

Inventors

  • 👤 Gordon H. Phillipps
  • 👤 David C. Humber
  • 👤 George B. Ewan
  • 👤 Barry A. Coomber
  • 👤 Anthony J. Pateman

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-02 02:17
CPC Classifications
C; C07; C07J; C07J41/00; C07J41/0005; C07J41/0011; A; A61; A61P; A61P9/00; A61P9/06; C07J63/00; C07J63/008; C07J71/00; C07J71/0005; C07J71/001

Claims Analysis

Total Claims: 19
Claim 1
Independent Claim 173 words
Compounds of the formula ##STR4## wherein R 1 is a C 1-8 alkyl group or a C 3-7 cycloalkyl group; R 2 is a C 1-6 alkyl group or a C 3-7 cycloalkyl group; R 3 is a hydroxy group or a group of formula --OR 4 or --OCOR 5 where R 4 is an alkyl or alkenyl group which may contain up to 6 carbon atoms (or such a group substituted by halogen, C 1-6 alkoxy, carboxy, phenyl, phenyl substituted by nitro, halo, C 1-4 alkoxy or C 1-4 alkyl), a C 3-7 cycloalkyl group, a phenyl group (or such a group substituted by nitro, halo, C 1-4 alkoxy or C 1-4 alkyl), or a carbon-attached 5-7 membered heterocyclic ring in which the hetero atom is selected from nitrogen, oxygen and sulphur, and R 5 is a hydrogen atom or a group R 4 as defined above; and the D-homo analogues thereof having the group --CO 2 R 2 (wherein R 2 is as defined above) at the 17aβ-position, and salts thereof.
Claim 2
Dependent Claim 173 words
Compounds of the formula ##STR4## wherein R 1 is a C 1-8 alkyl group or a C 3-7 cycloalkyl group; R 2 is a C 1-6 alkyl group or a C 3-7 cycloalkyl group; R 3 is a hydroxy group or a group of formula --OR 4 or --OCOR 5 where R 4 is an alkyl or alkenyl group which may contain up to 6 carbon atoms (or such a group substituted by halogen, C 1-6 alkoxy, carboxy, phenyl, phenyl substituted by nitro, halo, C 1-4 alkoxy or C 1-4 alkyl), a C 3-7 cycloalkyl group, a phenyl group (or such a group substituted by nitro, halo, C 1-4 alkoxy or C 1-4 alkyl), or a carbon-attached 5-7 membered heterocyclic ring in which the hetero atom is selected from nitrogen, oxygen and sulphur, and R 5 is a hydrogen atom or a group R 4 as defined above; and the D-homo analogues thereof having the group --CO 2 R 2 (wherein R 2 is as defined above) at the 17aβ-position, and salts thereof.
Claim 3
Dependent Claim 19 words
Compounds as claimed in claim 1 wherein R 1 is an isopentyl, hexyl, isohexyl, neohexyl, cyclopentyl or cyclohexyl group.
Claim 4
Dependent Claim 15 words
Compounds as claimed in claim 1 wherein R 2 is a methyl or ethyl group.
Claim 5
Dependent Claim 13 words
Compounds as claimed in claim 1 wherein R 3 is a hydroxy group.
Claim 6
Dependent Claim 15 words
Compounds as claimed in claim 1 in the form of physiologically acceptable acid addition salts.
Claim 7
Dependent Claim 30 words
Compounds as claimed in claim 5 in the form of hydrochloride, hydrobromide, phosphate, sulphate, p-toluenesulphonate, methanesulphonate, citrate, tartrate, acetate, ascorbate, lactate, maleate, succinate, tricarballylate, glutarate and glutaconate acid addition salts.
Claim 8
Dependent Claim 31 words
Compounds of formula (I) as claimed in claim 1 selected from: (a) methyl 2β,3α-dihydroxy-11α-(3-methylbutylamino)-5αp-androstane-17β-carboxylate; (b) methyl 11α-cyclohexylamino-2β,3α-dihydroxy-5α-androstane-17β-carboxylate; (c) methyl 3α-ethoxy-2β-hydroxy-11α-(3-methylbutylamino)-5α-androstane-17β-carboxylate; and (d) methyl 3α-acetoxy-2β-hydroxy-11α-(3-methylbutylamino)-5α-androstane-17β-carboxylate; and their physiologically acceptable acid addition salts.
Claim 9
Dependent Claim 35 words
Pharmaceutical compositions comprising at least one compound of formula (I) or D-homo analogue thereof as claimed in claim 1 or a physiologically acceptable salt thereof in admixture with one or more pharmaceutical carriers or excipients.
Claim 10
Dependent Claim 91 words
Compounds of the formula ##STR5## (wherein R 6 is a hydrogen atom, a C 1-8 alkyl group or a C 3-7 cycloalkyl group; R 7 is a hydrogen atom, a C 1-6 alkyl group or a C 3-7 cycloalkyl group; and R 3 is as defined in claim 1; with the proviso that at least one of R 6 and R 7 is a hydrogen atom) and the D-homo analogues thereof having the group --CO 2 R 7 (wherein R 7 is as defined above) in the 17aβ-position and salts thereof.
Claim 11
Dependent Claim 50 words
A method of therapy or prophylaxis of a human or animal body suffering from or liable to cardiac dysrhythmias which method comprises administering to the said body an effective amount of a compound of formula (I), a D-homo analogue thereof, or physiologically acceptable salt thereof as claimed in claim 1.
Claim 12
Dependent Claim 35 words
Compounds of formula (I), D-homo analogues thereof, and physiologically acceptable salts thereof as claimed in claim 1 for use in a method of treatment of the human or animal body to combat cardiac dysrhythmias therein.
Claim 13
Dependent Claim 15 words
Compounds as claimed in claim 2 wherein R 2 is a methyl or ethyl group.
Claim 14
Dependent Claim 13 words
Compounds as claimed in claim 2 wherein R 3 is a hydroxy group.
Claim 15
Dependent Claim 13 words
Compounds as claimed in claim 3 wherein R 3 is a hydroxy group.
Claim 16
Dependent Claim 22 words
Compounds as claimed in claim 2 wherein R 2 is a methyl or ethyl group and R 3 is a hydroxy group.
Claim 17
Dependent Claim 15 words
Compounds as claimed in claim 2 in the form of physiologically acceptable acid addition salts.
Claim 18
Dependent Claim 15 words
Compounds as claimed in claim 3 in the form of physiologically acceptable acid addition salts.
Claim 19
Dependent Claim 15 words
Compounds as claimed in claim 4 in the form of physiologically acceptable acid addition salts.

References Cited (Backward Citations)

US4353898A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1988-02-05 1988-08-06 1989-02-05 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1992-02-05 1992-08-06 1993-02-05 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1996-02-05 1996-08-06 1997-02-05 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag